0.05Open0.05Pre Close1 Volume129 Open Interest5.00Strike Price5.00Turnover6102.30%IV38.36%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1242Delta0.2279Gamma73.00Leverage Ratio-15.2203Theta0.0000Rho9.07Eff Leverage0.0000Vega
Mural Oncology Stock Discussion
NEWS
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
Mural Oncology presented data from its ARTISTRY-3 trial at the ASCO annual meeting, showing that less frequent dosing of nemvaleukin alfa (nemvaleukin), an engineered IL-2 cytokine, is well-tolerated and effective.
The trial shifted from five daily infusions to two infusions per three-week cycle, both as a single agent and in combination with pembrolizu...
NEWS
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
👃
👄
$Mural Oncology (MURA.US)$
No comment yet